R Tyler Hillman1, Amalia Sanchez-Migallon2, Larissa A Meyer1, Maria D Iniesta1, Katherine E Cain3, Ashley M Siverand1, Simone P L Veum1, Tina S Suki1, Javier D Lasala4, Pedro T Ramirez5. 1. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Gynecology and Obstetrics, Dexeus University Hospital, Barcelona, Spain. 3. Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: peramire@mdanderson.org.
Abstract
OBJECTIVE: To identify clinical and demographic characteristics associated with the absence of opioid usage on the day before discharge among patients undergoing open gynecologic surgery within an enhanced recovery after surgery (ERAS) program. METHODS: This was a single institution retrospective cohort study including all patients who underwent elective open gynecologic surgery as part of an ERAS program between November 1, 2014 and September 30, 2018 and who were discharged between post-operative day 2 and 7. Patients were excluded if they reported pre-existing chronic opioid use or underwent total pelvic exenteration. Descriptive statistics were used and multivariable logistic regression was used to identify factors associated with the absence of opioid usage on the day before discharge, after adjustment for relevant covariates. RESULTS: A total of 971 were included with a median length of stay of 3 days, and of these 526 (54.2%) used opioids on day before discharge and 445 (45.8%) did not. Absence of opioid use on the day before discharge was associated with age (P < .001), race (P = .04), Charlson Co-morbidity Index (P < .001), marital status (P = .004), and smoking status (P = .002) by univariate analysis. In a multivariable model, older age (adjusted OR 1.04; 95% CI 1.02-1.06; P < .001), current smoker status (adjusted OR 0.42; 95% CI 0.20-0.81; P = .01), and white or Caucasian race (adjusted OR 0.59; 95% CI 0.38-0.91; P = .02) were significantly associated with the absence of opioid use on the day prior to discharge. CONCLUSIONS: Nearly half of patients undergoing open gynecologic surgery within an established ERAS program did not consume any opioids on day before discharge. Safe, evidence-based reductions in post-operative opioid prescribing may be feasible for a subset of gynecologic surgery patients.
OBJECTIVE: To identify clinical and demographic characteristics associated with the absence of opioid usage on the day before discharge among patients undergoing open gynecologic surgery within an enhanced recovery after surgery (ERAS) program. METHODS: This was a single institution retrospective cohort study including all patients who underwent elective open gynecologic surgery as part of an ERAS program between November 1, 2014 and September 30, 2018 and who were discharged between post-operative day 2 and 7. Patients were excluded if they reported pre-existing chronic opioid use or underwent total pelvic exenteration. Descriptive statistics were used and multivariable logistic regression was used to identify factors associated with the absence of opioid usage on the day before discharge, after adjustment for relevant covariates. RESULTS: A total of 971 were included with a median length of stay of 3 days, and of these 526 (54.2%) used opioids on day before discharge and 445 (45.8%) did not. Absence of opioid use on the day before discharge was associated with age (P < .001), race (P = .04), Charlson Co-morbidity Index (P < .001), marital status (P = .004), and smoking status (P = .002) by univariate analysis. In a multivariable model, older age (adjusted OR 1.04; 95% CI 1.02-1.06; P < .001), current smoker status (adjusted OR 0.42; 95% CI 0.20-0.81; P = .01), and white or Caucasian race (adjusted OR 0.59; 95% CI 0.38-0.91; P = .02) were significantly associated with the absence of opioid use on the day prior to discharge. CONCLUSIONS: Nearly half of patients undergoing open gynecologic surgery within an established ERAS program did not consume any opioids on day before discharge. Safe, evidence-based reductions in post-operative opioid prescribing may be feasible for a subset of gynecologic surgery patients.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Ester Miralpeix; Alpa M Nick; Larissa A Meyer; Juan Cata; Javier Lasala; Gabriel E Mena; Vijaya Gottumukkala; Maria Iniesta-Donate; Gloria Salvo; Pedro T Ramirez Journal: Gynecol Oncol Date: 2016-03-09 Impact factor: 5.482
Authors: Cornelius A Thiels; Stephanie S Anderson; Daniel S Ubl; Kristine T Hanson; Whitney J Bergquist; Richard J Gray; Halena M Gazelka; Robert R Cima; Elizabeth B Habermann Journal: Ann Surg Date: 2017-10 Impact factor: 12.969
Authors: Brian T Bateman; Naida M Cole; Ayumi Maeda; Sara M Burns; Timothy T Houle; Krista F Huybrechts; Caitlin R Clancy; Stephanie B Hopp; Jeffrey L Ecker; Holly Ende; Kasey Grewe; Beatriz Raposo Corradini; Robert E Schoenfeld; Keerthana Sankar; Lori J Day; Lynnette Harris; Jessica L Booth; Pamela Flood; Melissa E Bauer; Lawrence C Tsen; Ruth Landau; Lisa R Leffert Journal: Obstet Gynecol Date: 2017-07 Impact factor: 7.661
Authors: Maureen V Hill; Ryland S Stucke; Sarah E Billmeier; Julia L Kelly; Richard J Barth Journal: J Am Coll Surg Date: 2017-11-30 Impact factor: 6.113
Authors: Larissa A Meyer; Javier Lasala; Maria D Iniesta; Alpa M Nick; Mark F Munsell; Qiuling Shi; Xin Shelley Wang; Katherine E Cain; Karen H Lu; Pedro T Ramirez Journal: Obstet Gynecol Date: 2018-08 Impact factor: 7.661
Authors: G Nelson; A D Altman; A Nick; L A Meyer; P T Ramirez; C Achtari; J Antrobus; J Huang; M Scott; L Wijk; N Acheson; O Ljungqvist; S C Dowdy Journal: Gynecol Oncol Date: 2016-01-03 Impact factor: 5.482
Authors: Allen A Mehr; Caroline Elmer-Lyon; Erin Maetzold; Catherine S Bradley; Joseph T Kowalski Journal: Female Pelvic Med Reconstr Surg Date: 2021-12-01 Impact factor: 2.091
Authors: Timothy P DiPeri; Timothy E Newhook; Elsa M Arvide; Whitney L Dewhurst; Morgan L Bruno; Yun Shin Chun; Hop S Tran Cao; Jeffrey E Lee; Jean-Nicolas Vauthey; Ching-Wei D Tzeng Journal: J Am Coll Surg Date: 2022-04-11 Impact factor: 6.532
Authors: Russell G Witt; Timothy E Newhook; Laura R Prakash; Morgan L Bruno; Elsa M Arvide; Whitney L Dewhurst; Naruhiko Ikoma; Jessica E Maxwell; Michael P Kim; Jeffrey E Lee; Matthew H G Katz; Ching-Wei D Tzeng Journal: J Surg Res Date: 2022-03-17 Impact factor: 2.417
Authors: Ross Harrison; Maria D Iniesta; Brandelyn Pitcher; Pedro T Ramirez; Katherine Cain; Ashley M Siverand; Gabriel Mena; Javier Lasala; Larissa A Meyer Journal: Int J Gynecol Cancer Date: 2020-08-26 Impact factor: 3.437
Authors: Katherine E Cain; Maria D Iniesta; Bryan M Fellman; Tina S Suki; Ashley Siverand; Camila Corzo; Javier D Lasala; Juan P Cata; Gabriel E Mena; Larissa A Meyer; Pedro T Ramirez Journal: Gynecol Oncol Date: 2020-12-06 Impact factor: 5.482
Authors: Isabel V Rodriguez; Paige McKeithan Cisa; Karen Monuszko; Julia Salinaro; Ashraf S Habib; J Eric Jelovsek; Laura J Havrilesky; Brittany Davidson Journal: JAMA Netw Open Date: 2022-07-01
Authors: R Tyler Hillman; Maria D Iniesta; Qiuling Shi; Tina Suki; Tsun Chen; Katherine Cain; Loretta Williams; Xin Shelley Wang; Jolyn S Taylor; Gabriel Mena; Javier Lasala; Pedro T Ramirez; Larissa A Meyer Journal: Int J Gynecol Cancer Date: 2020-11-06 Impact factor: 3.437
Authors: Sarah Huepenbecker; Robert Tyler Hillman; Maria D Iniesta; Tsun Chen; Katherine Cain; Gabriel Mena; Javier Lasala; Xin Shelley Wang; Loretta Williams; Jolyn S Taylor; Karen H Lu; Pedro T Ramirez; Larissa A Meyer Journal: Int J Gynecol Cancer Date: 2021-06-16 Impact factor: 4.661